Genetic Predisposition to Increased Blood Cholesterol and Triglyceride Lipid Levels and Risk of Alzheimer Disease: A Mendelian Randomization Analysis

In this study, Proitsi and colleagues use a Mendelian randomization approach to dissect the causal nature of the association between circulating lipid levels and late onset Alzheimer's Disease (LOAD) and find that genetic predisposition to increased plasma cholesterol and triglyceride lipid levels is not associated with elevated LOAD risk. Please see later in the article for the Editors' Summary

[1]  L. Ferrucci,et al.  Statins and serum cholesterol's associations with incident dementia and mild cognitive impairment , 2010, Journal of Epidemiology & Community Health.

[2]  M. Kivipelto,et al.  Midlife Serum Cholesterol and Increased Risk of Alzheimer’s and Vascular Dementia Three Decades Later , 2009, Dementia and Geriatric Cognitive Disorders.

[3]  S. Yusuf.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Commentary , 2002 .

[4]  Sudha Seshadri,et al.  Plasma total cholesterol level as a risk factor for Alzheimer disease: the Framingham Study. , 2003, Archives of internal medicine.

[5]  Tanya M. Teslovich,et al.  Discovery and refinement of loci associated with lipid levels , 2013, Nature Genetics.

[6]  Tanya M. Teslovich,et al.  Biological, Clinical, and Population Relevance of 95 Loci for Blood Lipids , 2010, Nature.

[7]  D. Clayton,et al.  Population structure, differential bias and genomic control in a large-scale, case-control association study , 2005, Nature Genetics.

[8]  S. Ebrahim,et al.  Mendelian randomization: can genetic epidemiology help redress the failures of observational epidemiology? , 2008, Human Genetics.

[9]  Hilkka Soininen,et al.  Evidence of the association of BIN1 and PICALM with the AD risk in contrasting European populations , 2011, Neurobiology of Aging.

[10]  J. Dietschy,et al.  Cholesterol metabolism in the brain , 2001, Current opinion in lipidology.

[11]  A. Butterworth,et al.  Mendelian Randomization Analysis With Multiple Genetic Variants Using Summarized Data , 2013, Genetic epidemiology.

[12]  Peter Holmans,et al.  Effects of Differential Genotyping Error Rate on the Type I Error Probability of Case-Control Studies , 2006, Human Heredity.

[13]  Nick C Fox,et al.  Common variants in ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer’s disease , 2011, Nature Genetics.

[14]  Robert C. Green,et al.  Statin use and the risk of Alzheimer’s disease: The MIRAGE Study , 2006, Alzheimer's & Dementia.

[15]  S Lovestone,et al.  Biomarkers for disease modification trials--the innovative medicines initiative and AddNeuroMed. , 2007, The journal of nutrition, health & aging.

[16]  Qian-Li Xue,et al.  Twenty-six-year change in total cholesterol levels and incident dementia: the Honolulu-Asia Aging Study. , 2007, Archives of neurology.

[17]  Thomas W. Mühleisen,et al.  Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease , 2013, Nature Genetics.

[18]  C. Björkelund,et al.  The 32-year relationship between cholesterol and dementia from midlife to late life , 2010, Neurology.

[19]  C. DeCarli,et al.  Associations between serum cholesterol levels and cerebral amyloidosis. , 2014, JAMA neurology.

[20]  G. D. Paolo,et al.  Linking lipids to Alzheimer's disease: cholesterol and beyond , 2011, Nature Reviews Neuroscience.

[21]  B. Pierce,et al.  Efficient Design for Mendelian Randomization Studies: Subsample and 2-Sample Instrumental Variable Estimators , 2013, American journal of epidemiology.

[22]  D. Lawlor,et al.  Re: Estimation of bias in nongenetic observational studies using "Mendelian triangulation" by Bautista et al. , 2007, Annals of epidemiology.

[23]  S. Feasson,et al.  MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20536 high-risk individuals : a randomised placebo-controlled trial. , 2008 .

[24]  Waddington Ch,et al.  Canalization of Development and Genetic Assimilation of Acquired Characters , 1959 .

[25]  D. Selkoe,et al.  Cholesterol level and statin use in Alzheimer disease: I. Review of epidemiological and preclinical studies. , 2011, Archives of neurology.

[26]  J. Dartigues,et al.  APOE genotype, cholesterol level, lipid-lowering treatment, and dementia , 2005, Neurology.

[27]  M. Sano,et al.  A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease , 2011, Neurology.

[28]  C. H. WADDINGTON,et al.  Canalization of Development and Genetic Assimilation of Acquired Characters , 1959, Nature.

[29]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease: Report of the NINCDS—ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease , 2011, Neurology.

[30]  Nick C Fox,et al.  Letter abstract - Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's Disease , 2009 .

[31]  H. Soininen,et al.  Serum cholesterol changes after midlife and late-life cognition , 2007, Neurology.

[32]  G. D. Paolo,et al.  Linking lipids to Alzheimer's disease: cholesterol and beyond , 2011, Nature Reviews Cancer.

[33]  K Yaffe,et al.  Midlife cardiovascular risk factors and risk of dementia in late life , 2005, Neurology.

[34]  Juan P Casas,et al.  Estimation of bias in nongenetic observational studies using "mendelian triangulation". , 2006, Annals of epidemiology.

[35]  A. Reiss.  Cholesterol and apolipoprotein E in Alzheimer's disease , 2005, American journal of Alzheimer's disease and other dementias.

[36]  Arto Mannermaa,et al.  Apolipoprotein E 4 Allele, Elevated Midlife Total Cholesterol Level, and High Midlife Systolic Blood Pressure Are Independent Risk Factors for Late-Life Alzheimer Disease , 2002, Annals of Internal Medicine.

[37]  D. Reich,et al.  Population Structure and Eigenanalysis , 2006, PLoS genetics.

[38]  C. Reitz.  Dyslipidemia and the Risk of Alzheimer’s Disease , 2013, Current Atherosclerosis Reports.

[39]  Andrew D. Johnson,et al.  SNAP: a web-based tool for identification and annotation of proxy SNPs using HapMap , 2008, Bioinform..

[40]  Manuel A. R. Ferreira,et al.  PLINK: a tool set for whole-genome association and population-based linkage analyses. , 2007, American journal of human genetics.

[41]  O. Hanon,et al.  Vascular risk factors, cognitve decline, and dementia , 2008, Vascular health and risk management.

[42]  P. Donnelly,et al.  A Flexible and Accurate Genotype Imputation Method for the Next Generation of Genome-Wide Association Studies , 2009, PLoS genetics.

[43]  Cedric Gondro,et al.  Quality control for genome-wide association studies. , 2013, Methods in molecular biology.

[44]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease , 1984, Neurology.

[45]  Miia Kivipelto,et al.  The Atorvastatin/Donepezil in Alzheimer’s Disease Study (LEADe): Design and baseline characteristics ⁎ ⁎ Roy W. Jones and Miia Kivipelto contributed equally to the content of the manuscript. , 2008, Alzheimer's & Dementia.

[46]  George Davey Smith,et al.  Mendelian randomization: Using genes as instruments for making causal inferences in epidemiology , 2008, Statistics in medicine.